Proton Therapy
Latin America · 1 shared keyword
Updated
Reviewed by Chandani Patel
Latin America Hereditary Cancer Testing Market Industry Trends and Forecast to 2034: Segmented by (Cancer, Test, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$425.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $232.8 Mn | — | — |
| 2025 (base) | $259.4 Mn | +$26.5 Mn | — |
| 2026 (forecast) | $288.9 Mn | +$29.6 Mn | +11.4% |
| 2027 (forecast) | $321.9 Mn | +$32.9 Mn | +24.1% |
| 2028 (forecast) | $358.6 Mn | +$36.7 Mn | +38.2% |
| 2029 (forecast) | $399.4 Mn | +$40.9 Mn | +54% |
| 2030 (forecast) | $445.0 Mn | +$45.5 Mn | +71.6% |
| 2031 (forecast) | $495.7 Mn | +$50.7 Mn | +91.1% |
| 2032 (forecast) | $552.2 Mn | +$56.5 Mn | +112.9% |
| 2033 (forecast) | $615.2 Mn | +$63.0 Mn | +137.2% |
| 2034 (forecast) | $685.3 Mn | +$70.1 Mn | +164.2% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $259.4 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $685.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Cancer, test and end user (see all) |
| Key players | Myriad Genetics, Inc., Ambry Genetics, Invitae, Natera, Quest Diagnostics (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Hereditary cancer testing looks for inherited gene changes, such as BRCA1 and BRCA2, that raise the risk of cancer.
Key segments of the hereditary Cancer Testing market include cancer (Breast and Ovarian, Colorectal (Lynch Syndrome) and Prostate) and test (Multi-Gene Panels, BRCA Tests and Whole Exome).
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the hereditary Cancer Testing market.
Routine use of genomics in screening, pharmacy and primary care gives the hereditary Cancer Testing market large room to grow.
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the hereditary Cancer Testing market.
The hereditary Cancer Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by ANVISA (Brazil)[1], ARCSA (Ecuador)[2], COFEPRIS (Mexico)[3], ANMAT (Argentina)[4], INVIMA (Colombia)[5] and ISP (Chile)[6]. How care is paid for in some of these countries: the SUS (Brazil)[7]; public care and IESS (Ecuador)[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)[9]; public care, obras sociales and prepaid plans (Argentina)[10]; social health insurance (EPS) (Colombia)[11]; and FONASA and ISAPREs (Chile)[12].
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] ANMAT. Checked 19 Nov 2026.
[5] INVIMA. Checked 19 Nov 2026.
[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.
[7] CONITEC. Checked 14 Nov 2026.
[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.
[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.
[12] FONASA. Checked 19 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hereditary Cancer Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Latin America.
What doctors and scientists are doing in Hereditary Cancer Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America · 1 shared keyword
Latin America
Latin America
Pharmaceuticals · Latin America
Digital Health · Latin America
Healthcare Services · Latin America
Pharmaceuticals · Latin America
Pharmaceuticals · Latin America
Healthcare Services · Latin America